Atherosclerosis Clinical Trial
Official title:
Acute Exposure to Diesel: Prolong Effects on Inflammation and Vasculature
Cross-over double-blind study. Healthy subjects will be exposed to diesel exhaust fumes and/or filtered air during a 2-hour session. Several parameters will be assesed i.e. endothelial function will be assessed with flow mediated dilation (FMD) techniques, arterial stiffness with pulse wave velocity (PWV) and reflected waves with augmentation index (AIx). C reactive protein (CRP), fibrinogen, protein C levels and protein S activity will be also measured. Heart rate variability and standard deviation of normal to normal intervals R-R intervals (SDNN) will be used to assess sympathetic activity. Measurements were assessed before, 2 and 24 hours after diesel exposure.
Introduction Diesel and its products represent one of the most common pollutants affecting
people living in urban and rural areas of the world. The majority of patients attending
emergency departments are likely to have been subjected to chronic exposure to diesel engine
exhaust fumes particularly those living in proximity to busy city roads and highways. Diesel
exhaust fumes are considered to contribute to over 50% of atmospheric particles with a mass
of less than 10 μM (PM10) average aerodynamic diameter, which is responsible for air
pollution. For fine particle matter lower than 2.5 μM (PM2.5) and extremely small particles
below 0.1 μM in diameter, the contribution to air pollution is much greater. These particles
are small enough to be inhaled and deposited in the lungs where they can exert deleterious
effects.
In Europe and Japan, epidemiological studies have demonstrated high rates of cardiovascular
morbidity, as well as acute and chronic respiratory disease, following occupational exposure
to diesel exhaust fumes. Experimental animal studies have also shown that exposure to diluted
diesel engine emission impairs left ventricle systolic performance, sympathetic drive,
fibrosis/fibrinolysis and accelerates atherosclerosis. Epidemiological studies and
experimental animal models are, however, rather imprecise regarding the mechanisms
responsible for these effects and the clinical impact of chronic diesel exhaust fumes
exposure. Moreover, although a relationship has been documented between acute coronary
syndromes (ACS) and acute exposure to diesel engine exhaust fumes, it is not known whether
relatively short-term exposure can cause prolonged inflammatory responses and/or affect
endothelial function and vessel wall properties in such a way as to potentially promote the
development of atherosclerotic changes.
The purpose of this study is to assess the impact of short-term exposure to Diesel exhaust
fumes on arterial elasticity, vascular function and inflammatory biomarkers.
Methods Study population Volunteers will be included in this randomized, double blind,
crossover study All volunteers who qualified for study entry will be free of cardiovascular
disease, hypertension, diabetes mellitus, pulmonary disease and acute inflammatory or chronic
diseases. Subjects who will be found to have an abnormal baseline 12-lead electrocardiogram
and/or impaired respiratory function tests will be excluded from the study.
Individuals taking cardiovascular medications, antioxidant or vitamin supplementation, oral
contraceptives or anti-inflammatory agents during the two months prior to inclusion in the
study will be excluded.
Women receiving hormone replacement therapy and premenopausal women with irregular menstrual
cycles will also excluded from the study. All women selected for the study will underwent
pregnancy tests before each study session.
Study Design This is randomized double-blind, cross-over study. All subjects will be exposed
to air or pollutants in two sessions which will took place 4 weeks apart between 8.00 and
10.00 a.m. in an ad hoc laboratory. In each session, the subjects will underwent a 2-hour
exposure period to controlled amounts of diesel exhaust fumes or filtered air. In each
session, measurements of markers of vascular function (flow mediated dilation, pulse wave
velocity and augmentation index), sympathetic activity and blood tests depicting the
inflammatory and fibrinolytic profile will took place. These measurements will be performed
at baseline (before exposure-T0), at the end of the 2-hour session (T2) and 24 hours after
the end of exposure (T24) (Figure 1).
Measurements in each women participating in the study will be performed at the same phase of
the menstrual cycle (late luteal phase). The participants will refrained from drinking
alcohol or caffeinated fluids and using medications containing caffeine, or smoking. All
volunteers will be assessed after having been in the fasting state for at least 8 h.
Participants will instructed to avoid changes in diet and physical activity habits during the
study period.
Diesel exhaust and filtered air exposure Volunteer exposure to diesel exhaust fumes will
carried out on a specially designed 30m2 room which was hermetically sealed. The diesel
exhaust fumes will be produced by a diesel engine (2500 cc and 100-150HP) and dispensed
through a pipe system into the exposure room. Prior to study entry, indoor levels of carbon
monoxide (CO) along with concentrations of fine airborne particulate matters (PM2.5) will be
measured, controlled and kept within the desired limits using portable environmental
instrumentation. In order to secure adequate levels of exposure to PM2.5 and CO, all
measurements will be controlled and compared to the respective standards of the European
Commission. Specifically, 25 µg/m3 (mean annual limit) for PM2.5 particles and 10 µg/m3
(maximum daily 8 hour mean) for CO.
Vascular measurements Endothelial function evaluation Using a linear array ultrasound (U/S)
transducer endothelial function will be evaluated by estimating flow mediated dilation (FMD)
in the brachial artery, as per standardized protocols.
Central arterial stiffness measurements Carotid-femoral pulse wave velocity (PWV), an index
of aortic stiffness, will be calculated from measurements of pulse transit time and the
distance between 2 recording sites (PWV = distance, in meters, divided by transit time, in
seconds) using a well-validated non-invasive device (SphygmoCor; AtCor Medical, Sydney,
Australia) as previously described.
Measurement of wave reflections The AIx of the central (aortic) pressure waveform will be
calculated as a composite index of wave reflections and arterial stiffness using a validated,
commercially available system (SphygmoCor; AtCor Medical, Sydney, Australia) which employs
the principle of applanation tonometry. Waveforms of radial pressure will be calibrated
according to sphygmomanometric systolic blood pressure and diastolic blood pressure measured
in the brachial artery. Because the AIx is influenced by changes in HR, it was corrected as
appropriate (corrected for a steady HR of 75 bpm; AI75).
Sympathetic activity assessment Heart rate variability (HRV) expresses the impact of the
autonomic nervous system on heart activity. Low HRV may be attributed to increased
sympathetic tone and has been found to be associated with increased cardiovascular morbidity
and mortality. Sympathetic activity will be evaluated by calculating HRV with continuous
electrocardiographic study (ECG) which was recorded for 20 minutes by a Holter device. ECG
data will then transferred onto a computer for assessment of HRV, which was performed in
accordance with current international guidelines, and standard deviation of normal to normal
intervals (SDNN) will be measured. (Holter software, Synescope, version 3.1, ELA Medical,
France).
Fibrinolysis and inflammation markers A fasting venous blood sample will collected by
venipuncture at baseline (before exposure-T0), at the end of the 2 hours session (T2) and 24
hours after the end of exposure (T24). Venous blood samples will be centrifuged at 3000 rpm
and serum was collected and stored at -80 C until assayed.
The prothrombotic status was assessed by measuring levels of fibrinogen using the
Multifibren® U system. Fibrinolytic activity will be assessed with measurements of protein C
plasma levels and protein S activity, which were measured by the STA® - Staclot® Protein C
kit and HemosIL™ Protein S Activity kits, respectively. Furthermore, changes from baseline in
the inflammatory profile induced by diesel exhaust fumes will be studied by measuring serum
C-reactive protein (CRP) using the Architect Abbott device.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05052918 -
The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes
|
N/A | |
Recruiting |
NCT04511234 -
Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease
|
N/A | |
Completed |
NCT05906797 -
Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Periodontitis.
|
N/A | |
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Suspended |
NCT02932176 -
Machine Learning for Handheld Vascular Studies
|
||
Recruiting |
NCT05158257 -
Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity
|
N/A | |
Completed |
NCT01212900 -
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
|
Phase 4 | |
Completed |
NCT03697382 -
Effect of Daily Steps on Fat Metabolism
|
N/A | |
Recruiting |
NCT06230406 -
T-Mem GEne in Atherosclerosis
|
||
Completed |
NCT03654313 -
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
|
Phase 1 | |
Completed |
NCT00382564 -
Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease
|
N/A | |
Recruiting |
NCT02894931 -
Effects of Dietary Interventions on Serum and Macrophage Atherogenicity
|
N/A | |
Completed |
NCT02998918 -
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
|
N/A | |
Not yet recruiting |
NCT02578355 -
National Plaque Registry and Database
|
N/A | |
Recruiting |
NCT02265250 -
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
|
||
Completed |
NCT02224339 -
New Technologies to Determine Carotid Plaque Vulnerability
|
||
Completed |
NCT02268513 -
Mediators of Atherosclerosis in South Asians Living in America (MASALA) Social Network Study
|
||
Completed |
NCT03393377 -
Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination
|
N/A | |
Not yet recruiting |
NCT01923012 -
Phase II Randomized Placebo-controlled Study With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis
|
Phase 2 | |
Completed |
NCT02377310 -
Pd/Pa vs iFR™ in an Unselected Population Referred for Invasive Angiography
|
N/A |